Research identifies early biomarker for insulin resistance, glucose intolerance in nondiabetic population

Metabolon, Inc., the leader in metabolomics-based biomarker discovery and analysis, today announced the publication of research that identified a novel, early biomarker for insulin resistance and glucose intolerance in a nondiabetic population. Co-authored by physicians and scientists from EGIR (European Group for the Study of Insulin Resistance) and Metabolon, the paper, "alpha-hydroxybutyrate Is an Early Biomarker of Insulin Resistance and Glucose Intolerance in a Nondiabetic Population", appears on the PLoS One website ( (doi:10.1371/journal.pone.0010883 (May 28th 2010)).

“alpha-hydroxybutyrate Is an Early Biomarker of Insulin Resistance and Glucose Intolerance in a Nondiabetic Population”

Metabolon's biochemical profiling technology was deployed on plasma samples from 399 nondiabetic subjects from EGIR's large prospective RISC (Relationship between Insulin Sensitivity and Cardiovascular Disease) cohort, representing a broad spectrum of insulin sensitivity and glucose tolerance. Alpha-hydroxybutyrate was the statistically top-ranked biochemical for classifying subjects as insulin resistant or insulin sensitive. Commenting on the study results, senior RISC author Ele Ferrannini, M.D. summarized, "From this unbiased, biochemical screen, alpha-hydroxybutyrate, an intermediate metabolite of amino acid metabolism, was the strongest biochemical that marks as a single metabolic fingerprint of in vivo human insulin resistance."

Insulin resistance is an abnormal metabolic condition and a recognized clinical predictor of type 2 diabetes and cardiovascular disease, with association with obesity, certain cancers, and other metabolic diseases. Metabolon is currently developing a fasted plasma diagnostic test for insulin resistance to allow physicians to more accurately assess their at-risk patient population. As described in the article, alpha-hydroxybutyrate and other metabolites have been identified as a metabolic signature of insulin resistance.




The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
You might also like... ×
Single BioNTech/Pfizer vaccine dose reduces risk of COVID-19 by nearly 52%, matching clinical trial data